ZBIO Stock Forecast & Price Target

Zenas BioPharma is viewed positively because obexelimab continues to show a differentiated profile in IgG4-RD, with week 52 cumulative glucocorticoid toxicity significantly lower than placebo (-11.4; p=0.021) and 12-month flare-free probabilities of 93% and 87% in the open-label extension, supporting durable disease control. Its reversible, non-depleting CD19/FcγRIIb mechanism, at-home subcutaneous weekly dosing, and early vaccine-response signals (6/7 influenza and 4/4 COVID-19) strengthen the case for a safer, more flexible long-term maintenance option versus B-cell depletion. The investment thesis is further reinforced by a large and expanding addressable market, with ~30–40K prevalent US cases, ~25K diagnosed and treated US patients, a ~$4B US commercial opportunity, and a key regulatory milestone on May 27, 2027.

Zenas BioPharma is vulnerable to clinical and regulatory setbacks because its lead asset, obexelimab, may fail to demonstrate sufficient efficacy, achieve the desired dosing intervals, or maintain a clean safety profile, any of which could halt development. Commercial risk is also elevated since the company may be unable to achieve sales estimates if obexelimab faces stronger competition from current or future therapies, limiting uptake even if approved. In addition, regulatory delays could strain financing requirements and weaken market confidence, leaving the stock heavily dependent on a single program with uncertain execution.